Bolt Biotherapeutics Inc — Quarterly Cash Flow (NASDAQ:BOLT) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Total assets 99.63 M85.86 M75.5 M65.05 M56.75 M Total liabilities 42.43 M39.05 M36.66 M32.95 M30.24 M Total equity 57.2 M46.81 M38.84 M32.1 M26.5 M Total liabilities & shareholders' equities 99.63 M85.86 M75.5 M65.05 M56.75 M Total debt ————— Net debt —————

뉴스

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

볼트 바이오테라퓨틱스 CEO 퀸, 주식 686달러 상당 매수

볼트 바이오테라퓨틱스 임원, 686달러 상당 주식 매수

Bolt Biotherapeutics CEO Quinn buys shares worth $686

Nemec, Bolt Biotherapeutics SVP, acquired shares worth $686

볼트 바이오테라퓨틱스, H.C. Wainwright ’매수’ 등급 개시

Bolt Biotherapeutics stock initiated with Buy rating at H.C. Wainwright

Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Mr. Cooper Gr (NASDAQ:COOP), Bolt Biotherapeutics (NASDAQ:BOLT)

볼트 바이오테라퓨틱스, 임상 데이터 지연 및 인력 절반 감축

Bolt Biotherapeutics delays clinical data, cuts workforce by half